Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc Cmn (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 58,941,392
  • Shares Outstanding, K 215,950
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.79
  • Price/Sales 5.14
  • Price/Cash Flow 11.52
  • Price/Book 4.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
267.10 +3.65%
on 04/11/17
278.69 -0.66%
on 04/24/17
+2.04 (+0.74%)
since 03/24/17
3-Month
250.02 +10.74%
on 01/25/17
298.00 -7.09%
on 03/03/17
+24.64 (+9.77%)
since 01/24/17
52-Week
205.43 +34.77%
on 06/27/16
307.33 -9.91%
on 08/02/16
+16.46 (+6.32%)
since 04/22/16

Most Recent Stories

More News
Biogen Idec Rises 1.31% on Heavy Volume: Watch For Potential Pullback

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $274.61 to a high of $277.00. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of...

BIIB : 276.86 (+1.44%)
3 Key Factors to Look Out for in Biogen's Q1 Results

With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

MRK : 62.14 (+0.40%)
LLY : 83.42 (+1.87%)
BMY : 53.55 (+0.13%)
BIIB : 276.86 (+1.44%)
Final Phase 3 Study Data Show SPINRAZA(R) (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy

--Positive Data Across a Broad Range of Individuals with SMA Presented at the American Academy of Neurology Annual Meeting

IONS : 45.74 (+3.34%)
BIIB : 276.86 (+1.44%)
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

LLY : 83.42 (+1.87%)
NVS : 74.61 (+1.65%)
BIIB : 276.86 (+1.44%)
What's in Store for Biogen (BIIB) this Earnings Season?

Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

CLDX : 3.22 (+0.62%)
ABBV : 64.66 (+1.32%)
AMGN : 163.14 (+1.70%)
BIIB : 276.86 (+1.44%)
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed

Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

MDCO : 51.45 (-0.73%)
BMRN : 93.52 (+5.71%)
OMED : 3.77 (+1.07%)
INCY : 123.91 (+0.73%)
IONS : 45.74 (+3.34%)
ALXN : 119.54 (+2.33%)
BIIB : 276.86 (+1.44%)
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
BMY : 53.55 (+0.13%)
BIIB : 276.86 (+1.44%)
Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress

--New SPINRAZA(R) Data Show Robust Efficacy and Safety Across a Broad Range of Individuals with SMA

BIIB : 276.86 (+1.44%)
Biogen to License Alzheimer Candidate from Bristol-Myers

Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
BMY : 53.55 (+0.13%)
BIIB : 276.86 (+1.44%)
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.38%

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $267.51 to a high of $273.14. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of...

BIIB : 276.86 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 280.80
1st Resistance Point 278.83
Last Price 276.86
1st Support Level 274.75
2nd Support Level 272.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.